The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Treatment options in type-2 low asthma
Open accessAbstract
Monoclonal antibodies targeting IgE or the type-2 cytokines interleukin (IL)-4, IL-5 and IL-13 are proving highly effective in reducing exacerbations and symptoms in people with severe allergic and eosinophilic asthma, respectively. However, these therapies are not appropriate for 30–50% of patients in severe asthma clinics who present with non-allergic, non-eosinophilic, “type-2 low” asthma. These patients constitute an important and common clinical asthma phenotype, driven by distinct, yet poorly understood pathobiological mechanisms. In this review we describe the heterogeneity and clinical characteristics of type-2 low asthma and summarise current knowledge on the underlying pathobiological mechanisms, which includes neutrophilic airway inflammation often associated with smoking, obesity and occupational exposures and may be driven by persistent bacterial infections and by activation of a recently described IL-6 pathway. We review the evidence base underlying existing treatment options for specific treatable traits that can be identified and addressed. We focus particularly on severe asthma as opposed to difficult-to-treat asthma, on emerging data on the identification of airway bacterial infection, on the increasing evidence base for the use of long-term low-dose macrolides, a critical appraisal of bronchial thermoplasty, and evidence for the use of biologics in type-2 low disease. Finally, we review ongoing research into other pathways including tumour necrosis factor, IL-17, resolvins, apolipoproteins, type I interferons, IL-6 and mast cells. We suggest that type-2 low disease frequently presents opportunities for identification and treatment of tractable clinical problems; it is currently a rapidly evolving field with potential for the development of novel targeted therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
Chung, K. F., Wenzel, S. E., Brozek, J. L., Bush, A., Castro, M., Sterk, P. J., Adcock, I. M., Bateman, E. D., Bel, E. H., Bleecker, E. R., et al. (2014) · European Respiratory Journal · doi:10.1183/09031936.00202013 · Cited by 3,926 · cited 1×
“Current ATS/ERS and GINA guidelines recommend thermoplasty be considered as an add-on therapy for selected adult patients with medically-optimised severe disease, performed within an independent systematic registry or clinical study[24, 100].”
BackgroundCluster analysis and clinical asthma phenotypes
Haldar, P., Pavord, I. D., Shaw, D. E., Berry, M. A., Thomas, M., Brightling, C. E., Wardlaw, A. J., & Green, R. H. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200711-1754oc · Cited by 1,987 · cited 3×
“Dysfunctional breathing is more common in type-2 low asthma[55] and responds to physiotherapy, leading to marked, sustained improvements in symptoms[109].”
BackgroundAfter asthma: redefining airways diseases
Pavord, I. D., Beasley, R., Agusti, A., Anderson, G. P., Bel, E., Brusselle, G., Cullinan, P., Custovic, A., Ducharme, F. M., Fahy, J. V., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)30879-6 · Cited by 1,073 · cited 3×
“Identifying and managing these ‘treatable traits’ may provide significant symptomatic benefit for individuals[56, 102].”
BackgroundSelf-citationInterleukin-1 and Related Cytokines in the Regulation of Inflammation and Immunity
Mantovani, A., Dinarello, C. A., Molgora, M., & Garlanda, C. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.012 · Cited by 1,046 · cited 1×
“process pro-IL-1 into its mature, secreted form[122].”
Role of deficient type III interferon-λ production in asthma exacerbations
Contoli, M., Message, S. D., Laza-Stanca, V., Edwards, M. R., Wark, P. A. B., Bartlett, N. W., Kebadze, T., Mallia, P., Stanciu, L. A., Parker, H. L., et al. (2006) · Nature Medicine · doi:10.1038/nm1462 · Cited by 1,006
Peters, U., Dixon, A. E., & Forno, E. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.02.004 · Cited by 934
Wong, C., Jayaram, L., Karalus, N., Eaton, T., Tong, C., Hockey, H., Milne, D., Fergusson, W., Tuffery, C., Sexton, P., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60953-2 · Cited by 600
Identification of IL6R and chromosome 11q13.5 as risk loci for asthma
Ferreira, M. A., Matheson, M. C., Duffy, D. L., Marks, G. B., Hui, J., Le Souëf, P., Danoy, P., Baltic, S., Nyholt, D. R., Jenkins, M., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60874-x · Cited by 381 · cited 6×
“Activation of IL-6TS reduces epithelial integrity and induces gene signatures associated with airway remodelling.”
BackgroundInfluentialImpaired innate interferon induction in severe therapy resistant atopic asthmatic children
Edwards, M. R., Regamey, N., Vareille, M., Kieninger, E., Gupta, A., Shoemark, A., Saglani, S., Sykes, A., Macintyre, J., Davies, J., et al. (2013) · Mucosal Immunology · doi:10.1038/mi.2012.118 · Cited by 214
Holloway, E. A., & West, R. J. (2007) · Thorax · doi:10.1136/thx.2006.076430 · Cited by 170
A Transcriptomic Method to Determine Airway Immune Dysfunction in T2-High and T2-Low Asthma
Peters, M. C., Ringel, L., Dyjack, N., Herrin, R., Woodruff, P. G., Rios, C., O’Connor, B., Fahy, J. V., & Seibold, M. A. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201807-1291oc · Cited by 151
Masefield, S., Edwards, J., Hansen, K., Hamerlijnck, D., Lisspers, K., van der Schee, M., Silva, L., Matthews, J., Gaga, M., Adcock, I., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.02295-2016 · Cited by 30 · cited 1×
“The need to develop novel biomarkers for specific type-2 low pathways, such as molecular microbiology and exhaled volatile organic compounds[121], and to understand the underlying pathological mechanisms are recognised research priorities[229], and the present refocussing of research on type-2 low disease holds genuin…”
Background
Cited by
Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma
Menzies-Gow, A., Corren, J., Bourdin, A., Chupp, G., Israel, E., Wechsler, M. E., Brightling, C. E., Griffiths, J. M., Hellqvist, Å., Bowen, K., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2034975 · Cited by 1,056
Biologic Therapies for Severe Asthma
Brusselle, G. G., & Koppelman, G. H. (2022) · New England Journal of Medicine · doi:10.1056/nejmra2032506 · Cited by 715
Self-citation
Metadata
- Authors
- Hinks, T. S. C., Levine, S. J., & Brusselle, G. G.
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2020-06-25
- Volume
- 57
- Issue
- 1
- Pages
- 2000528
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- OpenAlex
- W3037999771
- Cited by
- 187
- References
- 12
- FWCI
- 9.55
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.